Secondary analysis of late major gastrointestinal and genitourinary toxicities in unfavorable-risk prostate cancer patients receiving docetaxel: Insights from a randomized trial.
adverse event
chemotherapy
docetaxel
prostate cancer
radiation
radiotherapy
toxicity
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
01 Mar 2024
01 Mar 2024
Historique:
revised:
08
02
2024
received:
07
12
2023
accepted:
09
02
2024
medline:
1
3
2024
pubmed:
1
3
2024
entrez:
1
3
2024
Statut:
aheadofprint
Résumé
This study sought to evaluate the late toxicity associated with neoadjuvant and concurrent docetaxel and radiation therapy in patients with prostate cancer. A secondary analysis was performed of the phase 3 multicenter randomized trial (Dana-Farber Cancer Institute 05-043) including 350 patients with nonmetastatic unfavorable-risk prostate cancer. Patients were randomized 1:1 to receive androgen deprivation therapy, radiation therapy, and docetaxel versus androgen deprivation therapy and radiation therapy. The study assessed the cumulative incidence rates of grade 2 and grade 3 or higher gastrointestinal, genitourinary, and sexual toxicity. A multivariable Fine and Gray's competing risks regression model adjusted for age at randomization and pelvic lymph node radiation therapy was used to evaluate the treatment effect of docetaxel on time to late genitourinary and gastrointestinal toxicities. The study included 338 patients who primarily had minimal or no comorbidity (74.9%) and median age 66 years (interquartile range: 61,71). At a median follow-up of 10.2 years, docetaxel was not associated with increased risk of any grade 3 or higher (adjusted hazard ratio [AHR], 0.98; 95% confidence interval [CI], 0.36-2.67; p = .96) or grade 2 gastrointestinal (p = .75), genitourinary (p = .44), and sexual (p = .29) toxicity. Age was associated with increased grade 3 or higher (AHR, 1.08; 95% CI, 1.01-1.16; p = .03) and grade 2 gastrointestinal toxicity (AHR, 1.11; 95% CI, 1.03-1.20; p = .005). A nonsignificant trend (p = .09) toward increased late grade 3 or higher toxicity was observed for pelvic radiation therapy use. Docetaxel combined with radiotherapy has an acceptable long-term toxicity profile.
Sections du résumé
BACKGROUND
BACKGROUND
This study sought to evaluate the late toxicity associated with neoadjuvant and concurrent docetaxel and radiation therapy in patients with prostate cancer.
METHODS
METHODS
A secondary analysis was performed of the phase 3 multicenter randomized trial (Dana-Farber Cancer Institute 05-043) including 350 patients with nonmetastatic unfavorable-risk prostate cancer. Patients were randomized 1:1 to receive androgen deprivation therapy, radiation therapy, and docetaxel versus androgen deprivation therapy and radiation therapy. The study assessed the cumulative incidence rates of grade 2 and grade 3 or higher gastrointestinal, genitourinary, and sexual toxicity. A multivariable Fine and Gray's competing risks regression model adjusted for age at randomization and pelvic lymph node radiation therapy was used to evaluate the treatment effect of docetaxel on time to late genitourinary and gastrointestinal toxicities.
RESULTS
RESULTS
The study included 338 patients who primarily had minimal or no comorbidity (74.9%) and median age 66 years (interquartile range: 61,71). At a median follow-up of 10.2 years, docetaxel was not associated with increased risk of any grade 3 or higher (adjusted hazard ratio [AHR], 0.98; 95% confidence interval [CI], 0.36-2.67; p = .96) or grade 2 gastrointestinal (p = .75), genitourinary (p = .44), and sexual (p = .29) toxicity. Age was associated with increased grade 3 or higher (AHR, 1.08; 95% CI, 1.01-1.16; p = .03) and grade 2 gastrointestinal toxicity (AHR, 1.11; 95% CI, 1.03-1.20; p = .005). A nonsignificant trend (p = .09) toward increased late grade 3 or higher toxicity was observed for pelvic radiation therapy use.
CONCLUSIONS
CONCLUSIONS
Docetaxel combined with radiotherapy has an acceptable long-term toxicity profile.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 American Cancer Society.
Références
Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513-1520. doi:10.1056/nejmoa041318
Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502-1512. doi:10.1056/nejmoa040720
Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737-746. doi:10.1056/nejmoa1503747
Lin DW, Shih M, Aronson W, et al. Veterans Affairs Cooperative Studies Program Study #553: chemotherapy after prostatectomy for high-risk prostate carcinoma: a phase III randomized study. Eur Urol. 2020;77(5):563-572. doi:10.1016/j.eururo.2019.12.020
Rosenthal SA, Hu C, Sartor O, et al. Effect of chemotherapy with docetaxel with androgen suppression and radiotherapy for localized high-risk prostate cancer: the randomized phase III NRG Oncology RTOG 0521 trial. J Clin Oncol. 2019;37(14):1159-1168. doi:10.1200/jco.18.02158
James ND, Sydes MR, Clarke NW, et al. STAMPEDE investigators addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163-1177. doi:10.1016/s0140-6736(15)01037-5
Kellokumpu-Lehtinen PL, Hjalm-Eriksson M, Thellenberg-Karlsson C, et al. Investigators of the Scandinavian Prostate Cancer Study No. 13. Docetaxel versus surveillance after radical radiotherapy for intermediate- or high-risk prostate cancer-results from the prospective, randomised, open-label phase III SPCG-13 trial. Eur Urol. 2019;76(6):823-830. doi:10.1016/j.eururo.2019.08.010
Fizazi K, Carmel A, Joly F, et al. Updated results of GETUG-12, a phase III trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up. Ann Oncol. 2018;29:viii271. doi:10.1093/annonc/mdy284
Eastham JA, Heller G, Halabi S, et al. Cancer and Leukemia Group B 90203 (Alliance): radical prostatectomy with or without neoadjuvant chemohormonal therapy in localized, high-risk prostate cancer. J Clin Oncol. 2020;38(26):3042-3050. doi:10.1200/jco.20.00315
D’Amico AV, Xie W, McMahon E, et al. Radiation and androgen deprivation therapy with or without docetaxel in the management of nonmetastatic unfavorable-risk prostate cancer: a prospective randomized trial. J Clin Oncol. 2021;39(26):2938-2947. doi:10.1200/jco.21.00596
Mahal BA, Kwak L, Xie W, et al. Mortality risk for docetaxel-treated, high-grade prostate cancer with low PSA Levels. JAMA Netw Open. 2023;6(11):e2340787. doi:10.1001/jamanetworkopen.2023.40787
Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet. 2022;399(10336):1695-1707. doi:10.1016/s0140-6736(22)00367-1
American Society of Clinical Oncology. ASCO 2023: prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): results of PEACE-1, a Phase 3 Randomized Trial with a 2x2 Design. Accessed September 12, 2023. https://www.urotoday.com/conference-highlights/asco-2023/asco-2023-prostate-cancer/144889-asco-2023-prostate-irradiation-in-men-with-de-novo-low-volume-metastatic-castration-sensitive-prostate-cancer-mcspc-results-of-peace-1-a-phase-3-randomized-trial-with-a-2x2-design.html
Bolla M, Hannoun-Levi JM, Ferrero JM, et al. Concurrent and adjuvant docetaxel with three-dimensional conformal radiation therapy plus androgen deprivation for high-risk prostate cancer: preliminary results of a multicentre phase II trial. Radiother Oncol. 2010;97(2):312-317. doi:10.1016/j.radonc.2010.08.012
Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Contr Clin Trials. 1996;17(4):343-346. doi:10.1016/0197-2456(96)00075-x
Piccirillo J, Tierney R, Costas I, et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291(20):2441. doi:10.1001/jama.291.20.2441
Cupples LA, Gagnon DR, Ramaswamy R, D'Agostino RB. Age-adjusted survival curves with application in the Framingham study. Stat Med. 1995;14(16):1731-1744. doi:10.1002/sim.4780141603
Gaynor JJ, Feuer EJ, Tan C, et al. On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data. J Am Stat Assoc. 1993;88(422):400-409. doi:10.1080/01621459.1993.10476289
McVorran S, Keane T, Marshall DT. Long-term outcomes of a phase I trial of weekly docetaxel, total androgen blockade, and image guided intensity modulated radiation therapy for localized high-risk prostate adenocarcinoma. Adv Radiat Oncol. 2022;7(6):100935. doi:10.1016/j.adro.2022.100935
Talcott JA, Rieker P, Clark JK, et al. Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. J Clin Oncol. 1998;16(1):275-283. doi:10.1200/jco.1998.16.1.275
van As N, Tree A, Patel J, et al. 5-year outcomes from PACE B: an international phase III randomized controlled trial comparing stereotactic body radiotherapy (Sbrt) vs. conventionally fractionated or moderately hypo fractionated external beam radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2023;117(4):e2-e3. doi:10.1016/j.ijrobp.2023.08.027